Abstract

The study aimed to observe the effect of vincamine sustained-release capsules on the efficacy of patients with vestibular vertigo. 101 patients with vestibular vertigo were randomly divided into two groups, control group (n=51) and vincamine group (n=50); betahistine mesylate tablets (Minshilang) and vincamine sustained-release capsules (Orbran) were given to control and vincamine groups, respectively. The scores of dizziness disability inventory and patient health questionnaire were observed before treatment and after 1 w and 1 mo of treatment, and its influence on vertigo and depression in the two groups was evaluated as well. The data analysis showed that the number of females in the control group was significantly higher than that in males, indicating that the incidence of this disease is higher in females than in males. Dizziness handicap inventory scores of patients of two groups were analyzed and the results showed no significant difference between the groups (F=0.91 and p=0.343); there is a significant difference between different time points (F=427.42 and p=0.000) and interaction between therapeutic drugs at the same time (F=14.74 and p=0.000). Further analysis of the individual effects showed that there was no significant difference between the two groups before treatment (p=0.203), while there was a significant difference between the groups after 1 w and 1 mo of treatment (p<0.01). The patient health questionnaire 9 scores in two groups were analyzed and the results showed no significant difference between the groups (F=0.06 and p=0.938). There was a significant difference between different time points (F=150.13 and p=0.000) and interaction between therapeutic drugs at the same time (F=13.61 and p=0.000). Further analysis of the individual effects showed a significant difference (p<0.05) between the two groups before treatment. The depression level in the vincamine group was higher than that in the control group with no significant difference between the groups after 1 w of treatment (p=0.368). There was a significant difference (p<0.05) between the two groups after 1 mo of treatment and the depression level in the vincamine group was lower than that in the control group. The use of vincamine in the treatment of vestibular vertigo is more effective in controlling dizziness and depression over time than betahistine mesylate and has a long-term effect which is worthy of clinical promotion.